Manufacturer profile
AUG
Every published regulatory action recorded against this manufacturer, across all African authorities Drug Eye Africa monitors. Built strictly from published regulatory decisions and nothing else.
What these numbers are. They are counts of published regulatory actions recorded on this register. They are not a finding about the company, not an allegation, and not a measure of product quality. A manufacturer appearing here has had actions published against named products by named authorities; the actions speak for themselves and each one links to its primary notice.
3
Recorded actions
1
Countries
1
Authorities
0
Class I actions recorded
| Reference | Date | Country | Product | Batches | Action | Class | Source |
|---|---|---|---|---|---|---|---|
| DEA-EG-2025-0088 | Nov 2025 | EG | Zurcal40 mg gastro resistant tablets AUG | 230916 | Recall | Class II | Tier 1 · Regulator-published |
| DEA-EG-2025-0037 | Jul 2025 | EG | sansoimune syrup AUG | 231010 · 231011 · 230070 · 231009 · 230942 · 231012 · 230945 | Recall | Class II | Tier 1 · Regulator-published |
| DEA-EG-2025-0008 | Mar 2025 | EG | zurcal 40 mg Aug | 231244 | Recall | Class II | Tier 1 · Regulator-published |
Counts are of published regulatory actions recorded on this register. They are not a finding about the company, and this page says so.
Names as published
This profile groups 2 spellings used by the issuing authorities: AUG; Aug.
Company response
Drug Eye Africa has not yet invited a response from this company. That is our omission and not the company’s silence, and it is recorded here as one.
How this page is built
- Published regulator decisions only — no press reports, no allegations
- Name matching is conservative: only corporate-form suffixes are stripped, and a name that would reduce to a single token is kept whole
- Every action links to its primary notice